Tango Therapeutics Inc. (TNGX) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Tango Therapeutics Inc. (NASDAQ: TNGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $22.72 (+0.84% 1D, market cap $3.80B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TNGX ranks #426 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TNGX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.9%. By comparison, IRON (Disc Medicine Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -27.5%, cap $3.68B) and XENE (Xenon Pharmaceuticals Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.64B). Among the 5-stock peer group, OGN leads on earnings multiple (19.4x) while OGN leads on capital efficiency (24.9% ROIC).
Per TNGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819133), Tango Therapeutics Inc. generated $62.4M in revenue (+48.3% YoY), -$101.6M in net income, and -$139.9M in free cash flow against $398.7M in total assets and $23.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
FRED Regime × Technicals: 57% of 52W Range • RSI-14 at 46 (NEUTRAL RANGE)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While TNGX currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.54) and Max Pain ($23.86) forces dealer call-delta covering toward $36.11.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Tango Therapeutics Inc. (TNGX) advanced +0.84% to $22.72, trading at 57% of its 52-week range ($7.37 – $34.39). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $68 price target.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +48.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TNGX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TNGX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Tango Therapeutics Inc. (TNGX) ranks #426 by composite RQD confidence (44/100, grade D) and #186 by equity capitalization ($3.80B). Within this direct 5-issuer industry benchmark cohort, OGN leads on earnings valuation at 19.4x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with TNGX at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TNGX
ACTIVE
Tango Therapeutics Inc. | D | 44/100 | — | — | -28.9% | +0.84% | $3.80B | Benchmark Subject |
| IRON Disc Medicine Inc. | D+ | 54/100 | — | — | -27.5% | -2.41% | $3.68B | /iron-vs-tngx → |
| XENE Xenon Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | -0.35% | $3.64B | /xene-vs-tngx → |
| OGN Organon & Co. | B- | 70/100 | 19.4x | 53.3% | 24.9% | +0.22% | $3.63B | /ogn-vs-tngx → |
| AMLX Amylyx Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | +0.63% | $3.60B | /amlx-vs-tngx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tango Therapeutics Inc. (TNGX) reported GAAP revenue of $62.4M (+48.3% vs. FY2024 revenue of $42.1M , and +70.8% cumulative change since FY2023) , GAAP net income of -$101.6M, operating cash flow of -$138.9M, and free cash flow of -$139.9M (-5.8% YoY). On the balance sheet, TNGX closed FY2025 with $398.7M in total assets against $23.6M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $62.4M | -$101.6M | -$138.9M | -$139.9M | $398.7M | $23.6M |
| FY2024 (FY) | 2024-12-31 | $42.1M | -$130.3M | -$131.5M | -$132.3M | $316.5M | $52.6M |
| FY2023 (FY) | 2023-12-31 | $36.5M | -$101.7M | -$118.0M | -$119.6M | $2.09B | $488.9M |
As of 2026-11-02, Tango Therapeutics Inc. (NASDAQ: TNGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $22.72 (+0.84% 1D, market cap $3.80B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TNGX ranks #426 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TNGX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.9%. By comparison, IRON (Disc Medicine Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -27.5%, cap $3.68B) and XENE (Xenon Pharmaceuticals Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.64B). Among the 5-stock peer group, OGN leads on earnings multiple (19.4x) while OGN leads on capital efficiency (24.9% ROIC).
Per TNGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819133), Tango Therapeutics Inc. generated $62.4M in revenue (+48.3% YoY), -$101.6M in net income, and -$139.9M in free cash flow against $398.7M in total assets and $23.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
TNGX last traded at $22.72 (+0.84% on volume of 5,279,477 shares), positioning the stock -3.48% below its 50-day simple moving average ($23.54) and +1.29% above its 200-day simple moving average ($22.43). Across its 52-week range of $7.37 to $34.39, TNGX sits at the 56.8% percentile with a 14-day RSI of 46.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($19.88 to $25.56).
Why TNGX Stock advanced +0.84% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, TNGX scores 44 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
For a prospective investor evaluating the stock today, the rating points to a cash-burn profile. Operating margin is -60% and the company reports negative EPS (TTM) of -0.6. The balance-sheet pillar offers some comfort on solvency, but the cash-engine and insider-conviction pillars weigh the score down. The forward P/E of 28 is presented alongside negative trailing earnings, so the valuation depends on future earnings that the source data does not project. The rating is an analytical scoring output, not a recommendation.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $62.4M | $-111.3M | $-101.6M | N/A | $-139.9M | $112.3M | $23.6M |
| FY 2024 | $42.1M | $-145.6M | $-130.3M | N/A | $-132.3M | $69.5M | $52.6M |
| FY 2023 | $36.5M | $-114.2M | $-101.7M | N/A | $-119.6M | N/A | $488.9M |
Per the SEC financials, revenue grew from $36.5M (FY 2023) to $62.4M (FY 2025), while operating losses persisted in every period shown. Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -28.9%. Per the RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 5/9. Debt fell from $488.9M (FY 2023) to $23.6M (FY 2025), and reported cash was $112.3M at FY 2025, indicating a stronger balance sheet than the prior year despite ongoing cash burn.
Per the recent news section, headlines reference pancreatic cancer data, a JPMorgan rating reiteration ahead of ESMO data, comparisons to Revolution's results, updated vopimetostat combination data, a stock that has run 252%, and a report that the stock traded lower after cancer drug data. Each item is tagged YELLOW under the MARKET WIRE impact label. Per the Butterfly graph, there are no proprietary signals and no supply-chain links. Risk watch items include the trading-lower reaction to data and the valuation concern raised in the "fully valued" headline.
Real-time company headlines, analyst actions, and sector developments for Tango Therapeutics Inc. (TNGX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.
Welcome to the TNGX (Tango Therapeutics Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on TNGX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Tango Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on TNGX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $22.53 (52-wk range $7.37 - $34.39), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).